Clinical trials: how the label can make or break patient retention

Published: 6-Mar-2017
Packaging Regulatory

As the cost of drug development escalates, perhaps it’s time for industry to review its labelling infrastructure to alleviate the expense and implications of subject attrition

You need to be a subscriber to read this article.
Click here to find out more.

The importance of labelling in clinical trials gets very little exposure. However, as the global war for patients intensifies in an increasingly competitive market, and with subject attrition rates commonly shown to be between 15–20%, pharmaceutical companies are slowly discovering that the packaging of their products can be a key determinant of patient retention.

Although it might sound far-fetched, the reality is that if patients are unable to understand the instructions within the IFU (Information for Use), they are increasingly likely to give up. Moreover, it’s happening every day, on a global scale.

Think global, speak local

The globalisation of clinical trials has brought with it a convergence of logistical, operational and cultural challenges.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
See more

You may also like

Packaging

Adjust in time: Beware of the labelling challenges that Annex VI brings

Read more
Gordon Alexander and Simon Jones from PRISYM ID outline how imminent changes to EU clinical trial regulations will have major implications for labelling processes.

Trending Articles

  1. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  3. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  4. Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Packaging

Adjust in time: Beware of the labelling challenges that Annex VI brings

Gordon Alexander and Simon Jones from PRISYM ID outline how imminent changes to EU clinical trial regulations will have major implications for labelling processes.
Packaging

The recurring insanity of labelling recall — and how to avoid it

We’re all familiar with Einstein’s alleged definition of insanity: doing the same thing over and over and expecting different results. It’s a logic that translates beautifully to the labelling of medical devices, wherein a company’s continued reliance on manual processes and disparate labelling systems often culminates in pricey product recalls
Packaging

EU MDR does not draw distinctions

Ten steps to labelling implementation for both SMEs and large enterprises
Packaging

PRISYM ID introduces the Lifetime Partnership Programme (LPP)

The LPP aims to achieve the successful vision and objectives that underpin a growing labelling strategy
Packaging

A sticky situation for medical device manufacturers

The new EU regulation for medical devices will have major implications for labelling – will your labels comply?
Packaging

EU Medical Device Regulation (MDR) labelling compliance

Learning the lessons to avoid the nightmare
Packaging

Queen’s Awards to Enterprise 2013 winners announced

Suppliers to the pharmaceutical sector are recognised for International Trade and Innovation
Subscribe now